| Adais Johan Viruet-torres, APN | |
|
118 Bennett Dr Ste 130, Caribou, ME 04736-2052 | |
| (207) 498-3476 | |
| (207) 498-3534 |
| Full Name | Adais Johan Viruet-torres |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 118 Bennett Dr Ste 130, Caribou, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508596438 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | CNP221323 (Maine) | Primary |
| 363LF0000X | Nurse Practitioner - Family | 26NJ15044100 (New Jersey) | Secondary |
| Entity Name | Aroostook Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396858999 PECOS PAC ID: 1153233663 Enrollment ID: O20031104000020 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.
President Donald Trump's proposed rule that would make it more difficult for immigrants to gain permanent status if they use government aid programs could have a major impact in Texas, with its large immigrant population.
During his State of the Union address, President Obama signaled an openness to working with Republicans on ways to improve — but not undo — the health law. An area that seems open to such an effort is fixing the overhaul's 1099 tax reporting provision, which is gaining bipartisan support on Capitol Hill. But in terms of medical malpractice reforms, HHS Secretary Kathleen Sebelius noted key policy differences between the President and a GOP-sponsored House bill.
General Nutrition Centers, Inc., a leading global specialty retailer of nutritional products, today reported its financial results for the year and quarter ended December 31, 2009.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adais Johan Viruet-torres, APN 139 Chamberlain St, Brewer, ME 04412-1903 Ph: (207) 631-5106 | Adais Johan Viruet-torres, APN 118 Bennett Dr Ste 130, Caribou, ME 04736-2052 Ph: (207) 498-3476 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.
President Donald Trump's proposed rule that would make it more difficult for immigrants to gain permanent status if they use government aid programs could have a major impact in Texas, with its large immigrant population.
During his State of the Union address, President Obama signaled an openness to working with Republicans on ways to improve — but not undo — the health law. An area that seems open to such an effort is fixing the overhaul's 1099 tax reporting provision, which is gaining bipartisan support on Capitol Hill. But in terms of medical malpractice reforms, HHS Secretary Kathleen Sebelius noted key policy differences between the President and a GOP-sponsored House bill.
General Nutrition Centers, Inc., a leading global specialty retailer of nutritional products, today reported its financial results for the year and quarter ended December 31, 2009.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).
› Verified 1 days ago
Ms. Launa M Gonsioroski, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 163 Van Buren Rd, - Va Clinic, Caribou, ME 04736 Phone: 207-498-3800 | |
Lindsay Reynolds, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 74 Access Hwy, Caribou, ME 04736 Phone: 207-498-2356 Fax: 207-492-6260 | |
Mrs. Michelle Marie Deprey, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 163 Van Buren Rd Ste 2, Caribou, ME 04736 Phone: 207-498-2448 Fax: 207-498-2483 | |
Tanya L Sleeper, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 163 Van Buren Rd, Caribou, ME 04736 Phone: 207-498-1394 Fax: 207-498-1669 | |
Ms. Vanessa Elizabeth Mcdougall, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 14 Sweden St Ste 203, Caribou, ME 04736 Phone: 207-994-8404 | |
Shelly A Murphy, PMH-NP, PMHCNS, BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 7 Hatch Dr, Suite 245, Caribou, ME 04736 Phone: 207-492-1045 Fax: 207-492-1046 | |
Lori Bishop, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 74 Access Hwy, Caribou, ME 04736 Phone: 074-982-3562 |